


16 JUN  
2020

# CHEM VS. COVID TIMELINE


RECOVERY trial shows dexamethasone as first effective COVID-19 treatment

## The RECOVERY trial


The RECOVERY trial was started in March 2020 with the aim of identifying effective treatments for patients hospitalised with COVID-19. As new drug approvals can take many years, the trial focused on existing treatments for other diseases that could be repurposed to treat COVID-19.



Note: Figures shown were correct as of June 2021



On 16 June 2020, the RECOVERY trial reported dexamethasone as the first proven effective treatment for COVID-19. The trial started in the UK but has been expanded to Indonesia, Nepal, and Vietnam.



## How did it help?



### Saving lives

Treatment with the drugs that the RECOVERY trial has identified as effective saved the lives of patients who would otherwise have died from COVID-19.



### Collaboration

The RECOVERY trial works alongside other ongoing trials, such as the WHO's Solidarity trial, which are testing the efficacy of other treatments for COVID-19.



### Setting precedents

The RECOVERY trial has set a precedent for how large scale, user-friendly trials can be set up and run in an emergency situation that could be used in the future.

## What treatments were effective?

### Effective treatments

Dexamethasone and Tocilizumab were shown to be effective in patients with severe COVID-19. Both drugs have anti-inflammatory and immunosuppressant effects, which may explain the positive RECOVERY trial results.

### Estimated lives saved with dexamethasone treatment

22,000  
LIVES SAVED

1,000,000  
LIVES SAVED

Note: Estimates shown were correct as of March 2021

### Ineffective treatments

Several treatments were found to be ineffective, including hydroxychloroquine. Knowing which treatments are ineffective is also important so patients can get the best treatment possible.